IN.PACT™ AV Access Post-Approval Study (PAS002) (NCT04543539) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
IN.PACT™ AV Access Post-Approval Study (PAS002)
United States240 participantsStarted 2020-11-13
Plain-language summary
Long-term safety will be summarized
Who can participate
Age range
21 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Primary Cohort Inclusion Criteria:
* Patient is ≥ 21 years of age
* Patient has a mature native AV fistula created ≥ 60 days prior to the index procedure
* Patient has a de novo and/or non-stented restenotic lesion located between the arteriovenous anastomosis and axillosubclavian junction
* Patient has a target lesion or a tandem lesion that is ≤ 100 mm in length (by visual estimate) Note: Tandem lesions may be included provided they meet all of the following criteria: a. Separated by a gap of ≤ 30 mm (3 cm), b. Total combined lesion length, including 30 mm gap, ≤ 100 mm, c. Able to be treated as a single lesion
* Patient has a target vessel diameter of 4.0 - 12.0 mm (by visual estimate)
* Patient underwent successful crossing of the target lesion with the guide wire and pre-dilatation with a PTA balloon defined as: Residual stenosis of ≤ 30% AND Absence of a flow limiting dissection or perforation AND No extravasation requiring treatment
Primary Cohort Exclusion Criteria:
* Women who are breastfeeding, pregnant, or are intending to become pregnant, or men intending to father children
* Patient is receiving immunosuppressive therapy
* Patient has an infected AV access or systemic infection
* Patient with hemodynamically significant central venous stenoses that cannot be successfully treated prior to treatment of the target lesion
* Patient with target lesion located central to the axillosubclavian junction
* Patient has significant arterial inflow lesion requiring treatme…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.